Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2115 - NCI 9922: Phase 2 Study of Ibrutinib in Treatment-Refractory Distant Metastatic Cutaneous Melanoma (DMCM)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Melanoma

Presenters

Stergios Moschos

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

S.J. Moschos1, Z. Eroglu2, N.I. Khushalani2, K.L. Kendra3, G. Ansstas4, G.K. In5, P. Wang6, G. Liu7, F.A. Collichio1, C.C. Arrowood8, J.E. Reed1, N. Garrett-Mead8, N.E. Thomas1, D.W. Ollila1, S..P. Ivy9, A. Ivanova1, E.C. Dees1, J.L. Abbruzzese10

Author affiliations

  • 1 Medicine, Lineberger Comprehensive Cancer Center, 27599 - Chapel Hill/US
  • 2 Cutaneous Oncology Program, Moffitt Cancer Center, Tampa/US
  • 3 Cutaneous Oncology Program, Ohio State University Comprehensive Cancer Center - James, Columbus/US
  • 4 Medicine, Washington University School of Medicine in St. Louis, St. Louis/US
  • 5 Medicine, Keck School of Medicine at University of Southern California, Los Angeles/US
  • 6 Medicine, UK Markey Cancer Center, Lexington/US
  • 7 Medicine, University of Wisconsin, Madison/US
  • 8 Clinical Trials Unit, Duke Cancer Institute, Durham/US
  • 9 Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda/US
  • 10 Medicine, Duke Cancer Institute, Durham/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2115

Background

The IL-2 inducible kinase (ITK) is highly expressed in metastatic melanomas and molecular targeting and/or pharmacologic inhibition of ITK in preclinical melanoma models suppresses cell proliferation without inducing cell death (Carson CCR 2015). Ibrutinib suppresses proliferation of melanoma cell lines in low nM concentrations (Moschos ASCO 2017, TPS9592). We hypothesize that targeting DMCM with ibrutinib will induce antitumor responses, especially in high ITK-expressing melanomas.

Methods

This is an open-label, single-arm, Simon’s 2-stage design, multicenter, phase II study for patients (pts) with DMCM refractory to or ineligible for PD-1 and MAPK inhibitors, if BRAFV600-mutant. Given that the IC50 of ibrutinib for ITK is > 10 times than Bruton’s tyrosine kinase’s, we administered ibrutinib at 840mg qd. We hypothesized that an ineffective drug will have a = <5% response rate and = <18% 6-month PFS rate. We present the results of the first stage.

Results

18 pts (13 males; median age 63.5, range 37-82; 14 with M1c disease; 4 with BRAFV600 mutation; 12 with performance status 1 or 2; 4 with resistance to 4 treatments; 5 with resistance to = >5 treatments) were enrolled. Median exposure to ibrutinib was 27.5 days (range 4-155). The most frequent all-grade side effects were fatigue (55%), anorexia (50%), gastrointestinal upset (44%), and anemia (39%). 4 grade IV (hyponatremia, sepsis, cytokine release syndrome, and constipation occurred 6% each) and 9 grade III events [hyponatremia (17%); pneumonia, hypertension, anemia, hypoalbuminemia, dehydration, lymphopenia occurred 6% each] were seen. No antitumor responses were seen. At a median follow-up of 5 months, all pts had progressed (median PFS was 1.3 months, range 0.2-5.5). 15 pts were discontinued from study due to progression and 14 pts had died from melanoma. Median OS was 5 months (range 0.3-10.4 months) in pts who died.

Conclusions

In this treatment-refractory DMCM, high-dose ibrutinib did not induce any meaningful clinical benefit; therefore the study will not proceed to stage 2. Correlation between PFS and expression of ITK by melanoma cells and density of tumor-infiltrating T- and B-cells in pretreatment tumor specimens will be reported at the time of the meeting.

Clinical trial identification

NCT03427398.

Legal entity responsible for the study

NCI-CTEP.

Funding

NCI-CTEP, Pharmacyclics.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.